Utrecht, Netherlands

Patrick Engelberts

USPTO Granted Patents = 6 


Average Co-Inventor Count = 7.7

ph-index = 3

Forward Citations = 28(Granted Patents)


Location History:

  • Copenhagen, DK (2021)
  • Utrecht, NL (2020 - 2022)
  • Amersfoort, NL (2022)
  • Amersffoort, NL (2023)

Company Filing History:


Years Active: 2020-2023

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Patrick Engelberts

Introduction

Patrick Engelberts is a prominent inventor based in Utrecht, Netherlands. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies for cancer therapy. With a total of six patents to his name, Engelberts has established himself as a key figure in his area of expertise.

Latest Patents

Among his latest patents, Engelberts has developed multispecific antibodies that bind to CD3 and CD30. This invention includes pharmaceutical compositions comprising these antibodies, nucleic acids encoding them, and methods for their production. The applications of these antibodies are particularly relevant for cancer therapy. Additionally, he has worked on humanized or chimeric antibodies that bind to CD3, which also includes bispecific antibodies and their use in treating various diseases.

Career Highlights

Engelberts is currently associated with Genmab A/S, a leading biotechnology company known for its innovative approaches to cancer treatment. His work at Genmab has allowed him to focus on groundbreaking research and development in the field of immunotherapy.

Collaborations

Engelberts collaborates with notable colleagues such as Rik Rademaker and David Satijn. Their combined expertise contributes to the advancement of their projects and the overall mission of their organization.

Conclusion

Patrick Engelberts is a distinguished inventor whose work in antibody development has the potential to transform cancer therapy. His innovative patents and collaborations highlight his commitment to advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…